The angiotensin II type 2 (AT2) receptor promotes apoptosis and inhibits cell proliferation. In the present study, we investigated the role of the AT2 receptor in vascular repair and remodeling following severe vascular injury using AT2 knockout (AT2KO) mice. Left femoral arteries of AT2KO mice and wild-type (WT) control mice were injured by a 0.38 mm steel wire inserted from the lumen. Twenty-eight days after the injury, a concentric vascular wall thickening, composed largely of neointima, was noted both in AT2KO and WT mice. The area occupied by the neointima and the cell count within it were not different in the two mouse strains. However, the area of the medial layer and the cell count within it were significantly larger in AT2KO mice than in WT mice. A BrdU incorporation assay showed that the proliferative activity was high in the neointima but it was not different between the strains. On the other hand, apoptosis assessed by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) was significantly inhibited in the neointima and the media of AT2KO mice compared to the levels in WT mice. However, the number of TUNEL-positive cell was much smaller in the neointima than in the medial layer in both strains. Taken together, these results indicate that AT2 receptors promote the apoptosis of vascular cells but have no net effect on the neointimal cell growth or luminal narrowing after wire injury. The AT2 receptor may be involved in the control of medial layer thickness, at least in part, through medial cell apoptosis.
Shuchman M : Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006; 355: 1949–1952.
Peters S, Gotting B, Trummel M, Rust H, Brattstrom A : Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001; 13: 93–97.
Peters S, Trummel M, Meyners W, Koehler B, Westermann K : Valsaltan versus ACE inhibition after bare metal stent implantation-results of the VALVACE trial. Int J Cardiol 2005; 98: 331–335.
Harada K, Komuro I, Sugaya T, Murakami K, Yazaki Y : Vascular injury causes neointimal formation in angiotensin type 1a receptor knockout mice. Circ Res 1999; 84: 179–185.
Brede M, Hadamek K, Meinel L, et al: Vascular hypertrophy and increased P70S6 kinase in mice lacking the angiotensin II AT2 receptor. Circulation 2001; 104: 2602–2607.
Nakajima M, Hutchinson HG, Fujinaga M, et al: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995; 92: 10663–10667.
Stoll M, Steckelingl UM, Paul M, Bottari SP, Metzger R, Unger T : The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95: 651–657.
Mukawa H, Toki Y, Miyazaki Y, Matsui H, Okumura K, Ito T : Angiotensin II type 2 receptor blockade partially negates antihypertrophic effects of type 1 receptor blockade on pressure-overload rat cardiac hypertrophy. Hypertens Res 2003; 26: 89–95.
Kurisu S, Ozono R, Oshima T, et al: Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41: 99–107.
Suzuki J, Iwai M, Nakagami H, et al: Role of angiotensin II regulated apoptosis through distinct AT1 and AT2 receptors in neointimal formation. Circulation 2002; 106: 847–853.
Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ : Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272: 19022–19026.
Lehtonen JYA, Horiuchi M, Daviet L, Akishita M, Dzau VJ : Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 1998; 274: 16901–16906.
Yamada T, Horiuchi M, Dzau VJ : Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 1996; 93: 156–160.
Wang LX, Ideishi M, Yahiro E, Urata H, Arakawa K, Saku K : Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury. Hypertens Res 2001; 24: 179–187.
Lévy BI : Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the rennin-angiotensin system. Circulation 2004; 109: 8–13.
Oishi Y, Ozono R, Yoshizumi M, Akishita M, Horiuchi M, Oshima T : AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post myocardial infarction remodeling. Life Sci 2006; 80: 82–88.
Oishi Y, Ozono R, Yano Y, et al: Cardioprotective role of AT2 receptor in postinfarction left ventricular remodeling. Hypertension 2003; 41: 814–818.
Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK : Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744–747.
Sata M, Maejima Y, Adachi F, et al: A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointima hyperplasia. J Mol Cell Cardiol 2000; 32: 2097–2104.
Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study : a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Circulation 1992; 86: 100–110.
Faxon DP : Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol 1995; 25: 362–369.
Meurice T, Bauters C, Hermant X, et al: Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomized, double-blind, placebo-controlled trial. Lancet 2001; 357: 1321–1324.
Sata M, Sugiura S, Yoshizumi M, Ouchi Y, Hirata Y, Nagai R : Acute and chronic smooth muscle cell apoptosis after mechanical vascular injury can occur independently of the Fas-death pathway. Atheroscler Thromb Vasc Biol 2001; 21: 1733–1737.
Akishita M, Horiuchi M, Yamada H, et al: Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2000; 2: 13–20.
Tanaka K, Sata M, Hirata Y, Nagai R : Diverse contribution of bone marrow cells to neointimal hyperplasia after mechanical vascular injuries. Circ Res 2003; 93: 783–790.
Hilgers KF, Veelken R, Muller DN, et al: Renin uptake by endothelium mediates vascular angiotensin formation. Hypertension 2001; 38: 243–248.
Perlman H, Maillard L, Krasinski K, Walsh K : Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 1997; 95: 981–987.
Pollman MJ, Hall JL, Gibbons GH : Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury: Influence of redox state and cell phenotype. Circ Res 1999; 84: 113–121.
About this article
Cite this article
Yamamoto, Y., Watari, Y., Brydun, A. et al. Role of the Angiotensin II Type 2 Receptor in Arterial Remodeling after Wire Injury in Mice. Hypertens Res 31, 1241–1249 (2008). https://doi.org/10.1291/hypres.31.1241
- angiotensin II type 2
- vascular smooth muscle
Toll-like receptor 4 signaling has a critical role in Porphyromonas gingivalis-accelerated neointimal formation after arterial injury in mice
Hypertension Research (2016)
Journal of the Renin-Angiotensin-Aldosterone System (2010)